Aptargroup Stock Price, News & Analysis

Aptar (NYSE: ATR) was named one of America’s Most Responsible Companies 2026 by Newsweek for the seventh consecutive year, ranking 56 of 600 U.S. companies. The recognition covers ESG performance across Environment, Social and Governance and used 30+ KPIs plus a 26,000-person perception survey. Aptar highlighted investments in renewable energy, landfill-free site certifications, recyclable/refillable product design, and ongoing sustainability reporting.

Aptar (NYSE: ATR) announced on December 1, 2025 that it has acquired Sommaplast, a Brazil-based supplier of oral dosing pharma packaging including closures, droppers, dispensers and dosing cups.

Sommaplast operates a facility in Sao Paulo with a team of over 400 employees and more than 20 years of history. The acquisition expands Aptar's manufacturing footprint in Brazil alongside facilities in Cajamar, Jundiaí, Maringá and Camaçari and is framed as a move to strengthen presence in Latin America and capture growth in Brazil's oral dosing, OTC and nutraceutical markets.

Aptar (NYSE: ATR) announced it will present at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025. Stephan Tanda, President and CEO, will present at 7:00 a.m. Eastern Standard Time, with Vanessa Kanu, Executive Vice President and CFO, and Gael Touya, President Aptar Pharma, also available. A live audio webcast and presentation materials will be accessible in the Investors section of the company's website at www.aptar.com.

Aptar Digital Health (ATR) announced that the U.S. FDA granted 510(k) clearance on October 16, 2025 for HeroTracker® Sense, a Bluetooth-enabled Class II connected add-on sensor for pressurized metered-dose inhalers (pMDIs).

HeroTracker Sense is designed for users aged 12 and above, is compatible with commonly prescribed asthma and COPD inhalers including Ventolin HFA and Advair, and integrates with Aptar's Respiratory Disease Management Platform to provide real-time usage tracking, reminders, inhaler technique feedback, and educational resources via a mobile app.

Aptar (NYSE: ATR) was named one of the World’s Top Companies for Women 2025 by Forbes and Statista, marking the company’s fifth consecutive year on the list. Aptar is ranked 72 of 400 companies evaluated from an anonymous survey of over 120,000 women in 36 countries. The ranking is based on employer brand, public opinion and leadership score from surveys conducted over a two-year period.

AptarGroup (NYSE:ATR) has announced a 7% increase in its quarterly cash dividend to $0.48 per share, bringing the annualized dividend to $1.92 per share. The dividend will be paid on November 13, 2025, to stockholders of record as of October 23, 2025.

The company has demonstrated strong financial performance, having returned over $1 billion to shareholders through dividends and share repurchases since 2020. This increase positions Aptar to achieve its 32nd consecutive year of increasing total annual dividend, reflecting the company's sustained growth particularly in its Pharma segment.

AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, will host its 2025 Investor Day on Tuesday, September 9, 2025 from 9:00 a.m. to 12:00 p.m. EDT.

The event will feature presentations by executive management, followed by a Q&A session. In-person attendees will have access to an innovation demonstration and group lunch with management. While in-person attendance is invitation-only, the general public can access the event via webcast by registering online.

Presentation materials will be available on investors.aptar.com on the day of the event.

AptarGroup (NYSE:ATR), a leader in drug and consumer product technologies, reported strong Q2 2025 results with reported sales up 6% to $966 million and core sales growth of 3%. The company's net income increased 24% to $112 million, with earnings per share rising 25% to $1.67.

All three segments - Pharma, Beauty, and Closures - showed positive growth and margin expansion. Pharma segment saw 7% reported sales growth driven by strong demand in prescription medicines and injectables. Beauty segment reported 4% growth, while Closures segment achieved 8% growth led by food and beverage markets.

The company returned $100 million to shareholders through dividends and share repurchases in Q2. For Q3 2025, Aptar expects adjusted EPS of $1.53 to $1.61, anticipating continued strength in Pharma but normalization in naloxone sales.